Volume 13, No 6, Dec 2003
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 13 Issue 6, December 2003: 481-489
ORIGINAL ARTICLES
An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy
Zi Lai ZHANG1*, Wei Guo ZOU1*, Chun Xia LUO1, Bing Hua LI 1, Jin Hui WANG1, Lan Ying SUN1, Qi Jun QIAN2, Xin Yuan LIU1**
1Laboratory of Biotechnology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences, Shanghai 200031, China. E-mail: xyliu@sibs.ac.cn
2Eastern Heptobiliary Hospital, Second Military Medical University, Shanghai 200438, China
Correspondence: Xin Yuan LIU,(xyliu@sibs.ac.cn )
ONYX-015 is an attractive therapeutic adenovirus for cancer because it can selectively replicate in tumor cells and kill them. To date, clinical trials of this adenovirus have demonstrated marked safety but not potent enough when it was used alone. In this paper, we put forward a novel concept of Gene-ViroTherapy strategy and in this way, we constructed an armed therapeutic oncolytic adenovirus system, ZD55-gene, which is not only deleted of E1B 55-kD gene similar to ONYX-015, but also armed with foreign antitumor gene. ZD55-gene exhibited similar cytopathic effects and replication kinetics to that of ONYX-015 in vitro. Importantly, the carried gene is expressed and the expression level can increase with the replication of virus. Consequently, a significant antitumoral efficacy was observed when ZD55-CD/5-FU was used as an example in nude mice with subcutaneous human SW620 colon cancer. Our data demonstrated that ZD55-gene, which utilizing the Gene-ViroTherapy strategy, is more efficacious than each individual component in vivo.
FULL TEXT | PDF
Browse 1732
